Compugen reports Q3 EPS (11c), consensus (9c)

Cash, cash equivalents and cash investments were approximately $57.5M at quarter end vs. $83.7M as of December 31, 2022. The company expects existing cash and cash related balances to be sufficient to fund its current operating plan at least through the end of 2024. “In the second half of 2023, we continue to execute, and are delighted to see the continued advancement in the development of rilvegostomig derived from COM902 by our partner AstraZeneca who has progressed it into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemotherapy,” said CEO Anat Cohen-Dayag. “We completed patient enrollment in our microsatellite stable colorectal cancer proof-of-concept study with our unique triple immunotherapy combination and we are on track to report data in the first half of 2024. We presented new clinical data at SITC last week reinforcing previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy…Moving into next year, we look forward to presenting data in the first half of 2024 from our proof-of-concept study in metastatic colorectal cancer and completing enrollment of up to 20 patients from our platinum resistant ovarian cancer proof-of-concept study and to present data in 2024. Additionally, we are on track for IND filing in 2024.”